For its second fiscal quarter (ending June 30), Theravance Biopharma Inc (NASDAQ: TBPH) has reported E.P.S. of $-0.34 compared to $-0.28 a year ago. This performance was $-0.27 short of the consensus estimate of $-0.07. E.P.S. were $-0.92 for the latest four quarters through June 30 versus $-1.05 for the same period a year ago.
Recent Price Action
On 8/5/24, Theravance Biopharma Inc (NASDAQ: TBPH) stock declined slightly by -0.5%, closing at $9.59. NORMAL trading volume accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -6.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, TBPH is expected to be a Value Builder.
Theravance Biopharma has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Theravance Biopharma has a poor Power Rating of 28 and a poor Appreciation Score of 23, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment